Evolus Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EOLS Nasdaq 8731 https://www.evolus.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Evolus Inc

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 29th, 2023 8:05 pm
7 Small-Cap Stocks Analysts Predict Will Double in 2024 - Sep 13th, 2023 8:10 pm
Insider Sell: CFO Sandra Beaver Sells 3,178 Shares of Evolus Inc (EOLS) - Sep 9th, 2023 5:03 pm
Evolus, Inc. (NASDAQ:EOLS) is a favorite amongst institutional investors who own 56% - Sep 7th, 2023 4:44 pm
Evolus to Participate in September Conferences - Aug 29th, 2023 12:45 pm
Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside — Here’s Why You Should Pay Attention - Aug 27th, 2023 11:20 pm
Evolus Announces Inducement Grants for New Chief Marketing Officer - Aug 23rd, 2023 10:53 pm
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer - Aug 21st, 2023 12:45 pm
Insider Spends US$1.3m Buying More Shares In Evolus - Aug 18th, 2023 10:05 am
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline - Aug 8th, 2023 1:15 pm
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers - Aug 8th, 2023 12:45 pm
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates - Aug 2nd, 2023 9:45 pm
Evolus Reports Second Quarter 2023 Results and Provides Business Update - Aug 2nd, 2023 8:05 pm
Why Shares of Evolus Are Jumping Thursday - Jul 27th, 2023 3:42 pm
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue - Jul 27th, 2023 12:45 pm
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - Jul 26th, 2023 2:02 pm
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Jul 26th, 2023 12:45 pm
Evolus to Report Second Quarter 2023 Results and Provide Business Update - Jul 19th, 2023 12:45 pm
Twitter Faces Threats From AI and Threads - Jul 15th, 2023 11:30 am
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy - Jun 29th, 2023 1:00 pm